According to you, FDA panel might make a mistake to grant CLDN the Breakthrough Designation Therapy without looking at the info you presented?
I doubt that the company mislead the FDA on the CUPID1 data or the FDA shortsighted on the info you mentioned.
Why?
As far as I know, the FDA looks at clinical safety and efficacy to date. Their job isn't to determine whether or not a drug is working through the method of action claimed by the sponsor. Drugs get approved even though the claimed MOA is disproven; see DNDN.
If the FDA gave them BTD for CUPID1 data, it's fine. It doesn't mean that the pivotal trial will be successful.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.